Nordic Nanovector ASA Share Capital Increase

Nordic Nanovector ASA Share Capital Increase

Reference is made to the stock exchange announcement made by Nordic Nanovector ASA (OSE: NANOV) (the "Company") on 23 March 2022 regarding the settlement of 42,675 PSUs.

The share capital increase pertaining to the settled PSUs has now been registered in the Norwegian Register of Business Enterprises (the "NRBE") on 25 March 2022. The Company's share capital has been increased with NOK 8,535 through the issuance of 42,675 new shares.

Following registration of the share capital increase related to the new shares in the NRBE, the Company has an issued share capital of NOK 23,207,059.60, divided into 116,035,298 shares, each with a par value of NOK 0.20. Each share represents one vote in the Company's general meeting.

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of CD37-targeted therapies for haematological cancers and immune diseases. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 27 billion by 2029. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.

Nordic Nanovector's vision is to significantly advance the treatment of cancer patients with innovative targeted therapies.

We are a biopharmaceutical company dedicated to extending and improving the lives of patients with haematological cancers through the development and commercialisation of innovative targeted therapeutics.

We develop innovative targeted therapies using our proprietary CD37 platform that are designed to advance the treatment of patients with haematological cancers and immunological diseases.

The company's lead clinical-stage product is Betalutin®, a next generation radioimmunoconjugate (RIC), designed to improve upon and complement current options for the treatment of non-Hodgkin lymphoma (NHL). Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies.

We are committed to building a pipeline of novel radionuclide therapies.